Answers are grounded in this paper and cite their sources.
Artificial intelligence (AI) is increasingly being applied to retinal imaging for the detection, characterization, monitoring, and prediction of ischemic retinal disease. This narrative review examines the clinical applications and translational development of AI across retinopathy of prematurity (ROP), diabetic retinopathy (DR), and retinal vein occlusion (RVO). A structured literature search identified 18 primary studies spanning diagnosis and disease characterization, predictive and longitudinal applications, and clinical implementation. AI demonstrated strong performance across several imaging tasks, including plus-disease detection, DR detection and grading, RVO classification, angiographic interpretation, vascular quantification, and image-quality assessment. Predictive evidence of future clinical outcomes was more limited, with studies addressing ROP risk and short-term treatment response in RVO, while separate studies evaluated longitudinal vascular severity assessment in ROP. Translational maturity differed across diseases: DR had the strongest prospective and autonomous screening evidence, ROP had progressed toward quantitative assessment, prediction, and telemedicine support, and RVO remained predominantly at the retrospective development stage. Across all three diseases, high model performance did not necessarily indicate clinical readiness. Generalizability, image quality, interpretability, prospective validation, workflow integration, and evidence of downstream benefit remain important barriers to translation. The clinical value of retinal AI will ultimately depend not on achieving the highest performance metric, but on performing meaningful tasks reliably across settings and improving how patients are evaluated, referred, monitored, and treated.
No takes yet. Share an insight, caveat, or question.
Alexandre et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: